Please provide your email address to receive an email when new articles are posted on . The FDA approved insulin glargine-aglr, a second biosimilar to Sanofi’s insulin glargine, to improve glycemic ...
LONDON (Reuters) - A once-daily injection of Sanofi-Aventis's insulin drug Lantus controls blood sugar as effectively as Eli Lilly's Humalog, which needs to be taken three times daily, researchers ...
CHICAGO, June 29 (Reuters) - Dr. Louis Philipson has already started fielding calls from worried diabetics after new studies of 300,000 patients released on Friday suggested the Sanofi-Aventis insulin ...
The US Food and Drug Administration (FDA) has approved Eli Lilly's biosimilar version of insulin glargine, Rezvoglar KwikPen. This also made it "interchangeable" for Lantus (Sanofi) so that it could ...
HAMBURG, Germany ― Once-weekly tirzepatide (Mounjaro, Lilly) added to insulin glargine resulted in greater reductions in A1c along with more weight loss and less hypoglycemia compared with prandial ...
Shares of Viatris Inc. gained 3.3% in premarket trading on Thursday, the day after the Food and Drug Administration approved the first biosimilar verson of insulin glargine from Viatris and Biocon ...
U.S. regulators took action Wednesday that should make it easier to get a cheaper near-copy of a brand-name insulin at the drugstore. Doctors must now prescribe what's called a biosimilar drug, or OK ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved the second interchangeable insulin glargine biosimilar, Rezvoglar, to improve glycemic control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback